Alimera Sciences (NASDAQ:ALIM) Downgraded by HC Wainwright to Neutral

HC Wainwright downgraded shares of Alimera Sciences (NASDAQ:ALIM) from a buy rating to a neutral rating in a report issued on Tuesday, MarketBeat Ratings reports. HC Wainwright currently has $6.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Alimera Sciences’ Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS and Q4 2025 earnings at $0.14 EPS.

Several other equities research analysts have also issued reports on ALIM. StockNews.com lowered shares of Alimera Sciences from a buy rating to a hold rating in a research note on Tuesday, April 30th. Maxim Group started coverage on shares of Alimera Sciences in a research note on Monday, March 25th. They set a buy rating and a $10.00 target price on the stock.

Alimera Sciences Stock Up 0.2 %

Shares of NASDAQ ALIM opened at $5.53 on Tuesday. The company has a debt-to-equity ratio of 1.71, a quick ratio of 2.51 and a current ratio of 2.62. The firm has a market capitalization of $289.71 million, a price-to-earnings ratio of -3.52 and a beta of 1.14. The stock has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.68. Alimera Sciences has a 52-week low of $2.60 and a 52-week high of $5.65.

Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.08). Alimera Sciences had a negative net margin of 23.74% and a negative return on equity of 53.49%. The company had revenue of $23.01 million for the quarter, compared to analysts’ expectations of $23.72 million. During the same period last year, the firm earned ($0.71) earnings per share. Sell-side analysts expect that Alimera Sciences will post -0.13 earnings per share for the current year.

Institutional Trading of Alimera Sciences

A number of hedge funds have recently bought and sold shares of the business. Stonepine Capital Management LLC raised its holdings in Alimera Sciences by 0.4% in the 4th quarter. Stonepine Capital Management LLC now owns 3,999,459 shares of the biopharmaceutical company’s stock valued at $17,278,000 after acquiring an additional 15,773 shares during the last quarter. Vanguard Group Inc. raised its holdings in Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 396,506 shares during the last quarter. Worth Venture Partners LLC acquired a new stake in Alimera Sciences in the 3rd quarter valued at about $1,840,000. Ancora Advisors LLC acquired a new stake in Alimera Sciences in the 1st quarter valued at about $915,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in Alimera Sciences in the 1st quarter valued at about $169,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).